Hoover R David's Form 4 filing

Elanco Animal Health Inc (ELAN) · filed Dec 2, 2021

Accession no.: 0001179110-21-010543
Filed: Dec 2, 2021
Trade date: Nov 30, 2021
Filing delay: 2 days
Rule 10b5-1 plan: Not on the form (before 2023)

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $293.8K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Hoover R DavidCIK 0001186033	Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
Nov 30, 2021	Common Stock	PPurchaseAcquired	+10,000	$29.38^F1	+$293,800	105,000	Indirect
Nov 30, 2021	Common Stock	AGrant or awardAcquired	+7,307	$0.00^F2	$0	39,267	Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade date	Security	Transaction	Underlying shares	Unit price	Value	Held after	Ownership	Flags
Nov 30, 2021	Common Stock	AGrant or awardAcquired	+742.29	$28.74^F4,F5	+$21,333.41	18,858.55	Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

Reflects the weighted average price of 10,000 shares of common stock of Elanco Animal Health Inc. purchased by the reporting person in multiple transactions on November 30, 2021 with purchase prices ranging from $29.3587 to $29.40 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Referenced by the price of 1 transaction in Table I.

Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.

Referenced by the price of 1 transaction in Table I.

The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan.

Referenced by the price of 1 transaction in Table II.

The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $28.74 on November 30, 2021.

Referenced by the price of 1 transaction in Table II.

Remarks

Chairman of the Elanco Board of Directors

Read the full filing on SEC EDGAR (opens in a new tab)